The Press Lab at the Fred Hutchinson Cancer Research Center is devoted to the investigation of novel treatments for hematologic malignancies including non-Hodgkin's lymphoma, leukemia, and myeloma. We conduct basic laboratory investigations using leukemia and lymphoma cell lines and mouse xenograft models as well as human clinical trials. Agents currently under investigation include monoclonal antibodies, radioimmunoconjugates, immunotoxins, chemotherapeutic agents, and genetically modified cytotoxic T lymphocytes. In the clinical arena, we are continuing our successful program of high dose radioimmunotherapy with stem cell transplantation for B cell lymphomas and have trials planned investigating pretargeted radioimmunotherapy and gene therapy using adoptively transferred cytotoxic T lymphocytes bearing chimeric anti-CD20 receptors.
Dr. Oliver Press is currently the Acting Director of the Clinical Research Division and the Acting Senior Vice President of the Fred Hutchinson Cancer Research Center.